尿激酶联合雷珠单抗及氩激光治疗视网膜分支静脉阻塞继发黄斑水肿患者的观察

摘要

Objective:To evaluate effects of urokinase combined with ranibizumab and argon laser photocoagulation for treating macular edema secondary to branch retinal vein occlusion ( BRVO) . Methods:Twelve eyes of 12 patients with macular edema associ-ated with BRVO were included. All received 0. 05mL/(0. 5mg) of intravitreal injection with ranibizumab and intravenous administra-tion of urokinase one hundred thousand IU, then laser photocoagulation was performed 7 days later. The follow up was done 2 weeks and 4 weeks after the operation. The best-corrected visual acuity ( BCVA) and central macular thickness were measured after the treat-ment and compared with those at baseline. Results:The mean baseline BCVA was 0. 15±0. 11, and the mean central macular thick-ness was (556±113) μm. The mean BCVAs 2 and 4 weeks after the treatment were 0. 36±0. 16 (P=0. 034), and 0. 56±0. 16 (P=0. 032), respectively. The mean central macular thickness 2 and 4 weeks after the treatment were (315±89) μm (P=0. 039) and (255±50) μm (P=0. 008). Conclusions:Urokinase combined with ranibizumab and laser photocoagulation for treating macular ede-ma secondary to BRVO can improve BCVA and alleviate macular edema.%目的：探讨尿激酶联合雷珠单抗( Ranibizumab)及氩激光治疗视网膜分支静脉阻塞( ranch retinal vein occlusion, BRVO)继发黄斑水肿患者的效果。方法：12例(12只眼)BRVO继发黄斑水肿患者接受尿激酶10万单位静脉滴注联合玻璃体腔内注射雷珠单抗0.05 ml/(0.5 mg)及氩激光局部视网膜光凝,术后2周及4周后随访,对比治疗前后患者的最佳矫正视力(best-corrected visual acuity, BCVA)及黄斑中心凹厚度(central macular thickness, CMT)。结果：治疗前患者的最佳矫正视力为0.15±0.11,平均黄斑中心凹厚度为(565±113)μm,治疗后2周及4周患者的最佳矫正视力分别为0.36±0.16(P=0.034),0.56±0.12(P=0.032)；治疗后2周及4周患者的平均黄斑中心凹厚度为(315±89)μm(P=0.039),(255±50)μm (P=0.008)。结论：尿激酶联合雷珠单抗及氩激光治疗BRVO继发黄斑水肿,可以使患者的视力明显提高,促进黄斑水肿吸收。